Press "Enter" to skip to content

Merck’s Keytruda sets new five-year survival standard for advanced lung cancer

Nearly a quarter of patients who received Merck & Co’s immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting on Saturday.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/U9yCfTJ_z8k/mercks-keytruda-sets-new-five-year-survival-standard-for-advanced-lung-cancer-idINKCN1T233K

Also Read:   Cannabis tied to severe heart attack risk in younger adults